Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 19/20 | 0.61 |
| ▸ | CCNE1 | P24864 | 18/20 | 0.61 |
| ▸ | CCND1 | P24385 | 12/20 | 0.61 |
| ▸ | CDK6 | Q00534 | 12/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | CDK7 | P50613 | 1/20 | 0.50 |
| ▸ | CCNH | P51946 | 1/20 | 0.50 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.48 |
| ▸ | CDK4 | P11802 | 2/20 | 0.48 |
| ▸ | CDK9 | P50750 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19868137 | 0.89 | CCNE1 (0.61) | CDK2CCNE1CCND1CDK6MAPK8 | |
| SCHEMBL19868160 | 0.88 | CDK2 (0.60) | CDK2CCNE1CCND1CDK6MAPK8 | |
| SCHEMBL19868272 | 0.87 | CDK2 (0.59) | CDK2CCNE1CCND1CDK6MAPK8 | |
| SCHEMBL19868271 | 0.86 | MAPK8 (0.53) | CDK2CCNE1CCND1CDK6MAPK8 | |
| SCHEMBL19868286 | 0.84 | CDK2 (0.57) | CDK2CCNE1CCND1CDK6MAPK8 | |
| SCHEMBL19868142 | 0.84 | CDK2 (0.60) | CDK2CCNE1CCND1CDK6MAPK8 | |
| SCHEMBL17910154 | 0.83 | MAPK8 (0.60) | CDK2CCNE1CCND1CDK6MAPK8 | |
| SCHEMBL19868282 | 0.83 | CDK2 (0.54) | CDK2CCNE1CCND1CDK6MAPK8 | |
| SCHEMBL19868274 | 0.83 | CDK2 (0.54) | CDK2CCNE1CCND1CDK6MAPK8 | |
| SCHEMBL19868140 | 0.83 | CCNE1 (0.62) | CDK2CCNE1CCND1CDK6CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10233188-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044344-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | CDK2 1/4885CCNE1 29/4885CCND1 40/4885 |
| US-10233188-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | CDK2 1/4885CCNE1 29/4885CCND1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.